Prevalence of human papillomavirus infection and phylogenetic analysis of HPV-16 E6 variants among infected women from Northern Brazil by unknown
Tamegão-Lopes et al. Infectious Agents and Cancer 2014, 9:25
http://www.infectagentscancer.com/content/9/1/25RESEARCH ARTICLE Open AccessPrevalence of human papillomavirus infection and
phylogenetic analysis of HPV-16 E6 variants
among infected women from Northern Brazil
Bruna Pedroso Tamegão-Lopes1†, Edivaldo Costa Sousa-Júnior1, Fabio Passetti2, Carlos Gil Ferreira2,
Wyller Alencar de Mello1 and Rodrigo Vellasco Duarte Silvestre1*†Abstract
Background: The main cause of cervical cancer in the world is high risks human papillomavirus infection (mainly
represented by HPV-16 and HPV-18), that are associated to the development of malign transformation of the
epithelium. HPV prevalence exhibits a wide geographical variability and HPV-16 variants have been related to
an increased risk of developing cervical intraepithelial lesion. The aim of this study was to describe DNA-HPV
prevalence and HPV-16 variants among a women population from Northern Brazil.
Methods: One hundred and forty three women, during routine cervical cancer screening, at Juruti Project,
fulfilled an epidemiological inquiry and were screened through a molecular HPV test. HPV-16 variants were
determined by sequencing the HPV-16 E6 open reading frame.
Results: Forty two samples were considered HPV positive (29.4%). None of those had abnormal cytology results.
HPV prevalence varied between different age groups (Z(U) = 14.62; p = <0.0001) and high-risk HPVs were more frequent
among younger ages. The most prevalent type was HPV-16 (14%) and it variants were classified, predominantly, as
European (87.5%).
Conclusions: HPV prevalence in our population was higher than described by others and the most prevalent HPV
types were high-risk HPVs. The European HPV-16 variant was the most prevalent among HPV-16 positive samples. Our
study reinforces the fact that women with normal cytology and a positive molecular test for high-risk HPVs should be
submitted to continuous follow up, in order to verify persistence of infection, promoting an early diagnosis of cervical
cancer and/or its precursors.
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Human papillomavirus (HPV) is a large group of epithe-
liotropic viruses of more than 160 different types. HPVs
are very successful infectious agents – inducing chronic
infections that have no systemic sequelae, rarely killing
the host and shedding large amounts of infectious parti-
cles for transmission [1]. However, a dozen of the 40
HPV types that infect the human body are associated
with probable or definite oncogenic risk [2].* Correspondence: rodrigosilvestre@iec.pa.gov.br
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article, unless otherwise stated.High-risk HPVs (hrHPV), which includes HPV type 16
(HPV-16), are etiological agents of cervical cancer [3-5],
being the persistent of hrHPV infection, known as the
integrated HPV DNA into host genome, in the presence
of other environmental and host factors, a necessary step
for the development of high-grade cervical intraepithe-
lial neoplasia and invasive cervical cancer [6-9]. Cervical
cancer is the third most common cancer in women and
more than 85% of the global burden occurred in devel-
oping countries, causing 275,000 deaths in 2008, with
31,400 of those deaths occurring in Latin America [10].
HPV molecular variants are defined taxonomically
based on L1 coding region of the DNA sequence [11]. The
comparative nucleotide sequence analysis, that includesCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Distribution of socio-demographic characteristics
of the 143 women included in this study




Single or live with partner 66 (46)
Widow 1 (1)





Basic Education 83 (58)




Government employee 17 (12)
Student 11 (8)
Husbandman 11 (8)
Sex worker 7 (5)
Teacher 5 (3)
Retired 4 (3)
Nursing assistant 4 (3)
Others 21 (14)












Which? Condyloma: 3 (27.5)
Syphilis: 3 (27,5)
Vaginal discharge: 1 (9)
Gonorrhea: 1 (9)
Trichomoniasis: 1 (9)
Not informed: 2 (18)
No 120 (84)
Not informed 12 (8.3)
Table 1 Distribution of socio-demographic characteristics
of the 143 women included in this study (Continued)
Use of condom in
sexual intercourse?
Yes 30 (21)
No 107 (75) 0.6536
Not informed 6 (4)
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nucleotide sequence by no more than 2% in the coding
regions and until a 5% in the non coding region, evolved
into six major phylogenetic branches: European (E), Asian
(As), Asian-American (AA), African-1 (Af1), African-2
(Af2) and North-American (NA1) [5,12,13]. Instead only a
small portion of HPV-16 infections persist, several studies
from Europe and the Americas, based principally on the
sequencing of E6 and/or the LCR, had suggested that
HPV-16 variants can influence viral persistence and the
development of cervical cancer [14,15].
The aim of this study was to describe HPV infection
prevalence and related epidemiological variables, as well
as, the HPV-16 variants circulating in a population of
women from Northern Brazil.
Results
Socio-demographic data was obtained for a total of 143
women. Data analysis revealed that these women had 34
years median age (SD ± 13.74 y; 95% CI 32-36), were
married (48%), had basic education as the main school
level (58%), had housewife occupation (35%), were not
exposed to alcohol (58%) or to tobacco (86%), had no
history of STD’s (Sexual Transmitted Diseases) (84%),
had 16 years old (SD ± 2.9 y; 95% CI 15.5-16.5) as the
median age of the first sexual intercourse and had a
median of 10 sexual partners (SD ± 32.3 partners; 95%
CI 4.3-15.3). The higher median observed on the vari-
able number of sexual partners was probably influenced
by data related to women that referred to be sex workers
(n = 7). When these data was removed from analysis,
observed media of sexual partners was 5.5 partners
(SD ± 8.6 partners; 95% CI 4-7). There was no observed
statistical association between the described variables
and the occurrence of HPV infection in our population
(p > 0.05) (Table 1).
All of the 143 samples included in this study had nor-
mal cytology results. 23 HPV negative samples (23/101;
23%) had exhibited no amplification of internal control
gene and were considered inadequate for subsequent
analysis. Linear Array HPV Genotyping Test® (Roche
Molecular Systems, Alameda, CA) results revealed that
78 samples were negative (78/120; 65%) and 42 were
positive (42/120; 35%) for HPV infection. Among the
HPV positive samples, the high risk HPV-16 was the
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and HPV-45 (7%). Among low risk HPV types HPV-62
(7%) was the most frequent. The others high and low
risk HPV types were identified in low frequencies (<2,5%
each). From those HPV-16 positive samples, six were
HPV-16 single infection (14.3%) and five were multiple
infections that included HPV-16 (12%) (Table 2).
There was a variation of HPV prevalence between
different age groups (Figure 1) and age was associated
with HPV prevalence (Z(U) = 14.62; p = <0.0001). HPV
of low and high risk was more prevalent among women
at younger ages (<25 years) (37.8%; 95% CI 31.6%-44%)Table 2 Distribution of HPV types according to Array HPV
Genotyping Test® results



















16 + 18 1 (2.4)
16 + 31 1 (2.4)
16 + 59 1 (2.4)
16 + 31 + 52 1 (2.4)
16 + 51 + 56 1 (2.4)
52 + 58 1 (2.4)
56 + 39 1 (2.4)
61 + 81 1 (2.4)
35 + 52 + 59 1 (2.4)
45 + 51 + 62 1 (2.4)
45 + 55 + 61 1 (2.4)
45 + 58 + 61 1 (2.4)
11 + 53 + 84 + GTCP6108 1 (2.4)
Indeterminate 1 (2.4)and hrHPV types were more prevalent among 25-34 age-
group women (31.3%; 95% CI 26.9%-36.4%) (Table 3).
Phylogenetic analysis was performed for a total of 8
samples among the HPV-16 positive samples (73%). The
phylogenetic tree segregated into four major branches
that could be recognized as European (EUR), Asian (As),
African (including Afr1 and Afr2) and American (including
Asian-American and North-American) lineages. The
HPV-16 variants were classified as European (87.5%)
and American (12.5%) (Figure 2).
Discussion
In the present study we found a 29.4% HPV prevalence
between women without abnormal cytology screened by
Pap Smear Test, at Juruti, Northern Brazil. This preva-
lence was higher than that described by SanJosé et al
[16], in meta-analysis of a systematic literature review
of HPV prevalence among women with normal cervical
cytology worldwide, where global and South America
prevalence’s were 10.4% and 12.3%, respectively. As well
as, that described by Bruni et al [17], in meta-analysis
of one million women with normal cytological findings,
where global and South America prevalence’s were
11.7% and 15.3%, respectively. A broader range of HPV
prevalence (from 10.4% to 24.5%) has been described in
Brazilian studies including women with normal cytology.
Our result was similar to that described by the Latin
America Screening Study (24.5%) [8] and to data related to
Amazonas State (29.2%) [18]. However, it was lower than
described in others Brazilian studies including women
populations from Rio Grande do Sul (34%), São Paulo
(58.4%), Distrito Federal (62%) and Rio de Janeiro (63.6%)
[19-21].
A marked variation of HPV prevalence among age
groups was observed in our population. Women with
less than 25 years and comprehend between 25-34 years
were more predisposal to have a positive HPV-DNA test,
including for hrHPV types. Some studies in Central and
South America have demonstrated a first peak prevalence
of HPV infection in women below age 25 and a second
peak after age 55 [22,23] which corroborates our data.
The first peak suggest that women acquire infection in the
first few years after become sexually active and the second
peak suggest that middle-age women harbor long-term
HPV persistent infections or new incident infections,
which might also reflect changes in hormonal or immuno-
logical status [24,25].
HPV-16 was the most prevalent type observed in our
study (14.3%), followed by HPV-52 and HPV-45. The
most prevalent HPV types described in women with
normal cytology are HPV-16, -58, -31, -18, -45 and -52,
however, it is well documented that this prevalence is
lower than that observed among women with HSIL
(high-grade lesions) and SCC (squamous-cell carcinoma)
R2=0.9248
R2=0.8587
Figure 1 Age-group and HPV infection prevalence. High risk HPVs – dotted line; All HPV types – full line.
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than that described in Natal (Northeast Brazil) (12.7%)
[27] and lower than that observed in Rio Grande do Sul
(19.6%), Rio de Janeiro (19%), São Paulo (18.2%) and
Amazonas (31.8%) [18-21].
Phylogenetic analysis based on E6 sequences of eight
HPV-16 isolates allowed the identification of seven
European and only one non-European variants. A previ-
ous study realized in Belém (Northern Brazil) exhibited
a higher prevalence of Asian-American (43.2%) and
European (42%) variants among women with cervical
cancer [28]. Previous data suggests that women harboring
non-European HPV-16 variants have an 2- to 9- fold
increased risk of cervical cancer [29,30], however, it has
been reported that HPV-16 European variants persists
longer in white women [31-33].
Genital HPV infection is one of the most common
sexually transmitted infections worldwide. It has been
estimated that approximately 10% of women worldwide
with normal cytological findings carry a detectable cervical
HPV infection, depending on the HPV testing technology,
study size, and the age groups and geographical region
studied [34]. It is necessary to emphasize that women with
one positive DNA test for HPV-16, as well as, for others
hrHPV, need to be followed-up to confirm persistentTable 3 Distribution of age-group according to HPV infection
Age at sample collection Nº of women HPV +
<25 45 17 (37.8
25-34 32 12 (37.5
35-44 38 7 (18.4)
45-54 17 3 (17.6)
>54 11 3 (27.3)
Total 143 4
Legend: hrHPV – high risk HPV.infection, to monitor and to avoid late diagnosis of pos-
sible cervical cancer and its precursors, since it is well
documented that HPV-16 and HPV-18 account for 70% of
all cervical cancer cases worldwide. This will be only
achieved through consistent cervical screening associated
with alternative screening tools as molecular techniques.
A major limitation of the present study is represented
by the modest sample size and by the absence of a follow-
up period to confirm persistence of HPV infection or
clearance through timeline, as well as, the lack of ethnicity
data, which was expected to be associated with HPV-16
variants. Another limitation was related with no ampli-
fication of internal control (β-globin gene) between 23
cervical samples on the Linear Array HPV Genotyping
Test®. Those results were probably caused by inadequate
sample cellularity (yield DNA specimens), as the DNA
extraction technique was held as a constant, with DNA
isolated using the same commercial kit.
Conclusion
HPV prevalence (29.4%) in a population of women with
normal cytology from Juruti (Northern Brazil) is higher
than described by others with the most prevalent HPV
types being hrHPVs (HPV-16, -52 and -45). The European
HPV-16 variant (87.5%) is the most prevalent among(%) (CI 95) hrHPV + (%) (CI 95) p
) (31.6%-44%) 11 (24.4) (20.4%-28.4%)
<0.0001
) (31.4%-43.6%) 10 (31.3) (26.9%-36.4%)
(15.4%-21.4%) 5 (13.2) (11%-15.4%)
(14.7%-20.5%) 2 (11.8) (9.9%-13.7%)
(22.8%-31.8%) 1 (9.1) (7.6%-10.6%)
2 (29.4) 29 (20.3)
Figure 2 HPV-16 phylogenetic tree based on E6 sequencing. A phylogenetic tree was constructed using the RaxML program. This is a
bootstrapped (1.000 replicates) consensus Maximum-Likelihood tree. PPH16 – GenBank accession number K02718 (HPV-16R). American branch
(light blue) includes North American (NA) and Asian-American (AA) variants.
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carcinogenic agent and is associated with cervical cancer
among carriers. Despite being descriptive, the present
study reinforces the necessity to follow up women with
normal cytology, meanwhile, with a positive molecular
test for hrHPVs, to determine persistence of infection




Samples were collected from patients included on the
Juruti Project, a research project designed to investigate
the impact of migratory flow on the incidence and
prevalence of sexual transmissible diseases. Juruti is a
county located in the West Region of the State of Pará
that had an estimated population of 34.338 individuals in
the year of 2007. The main economical activities of Juruti
are agriculture and mining and this county is marked by
migratory flow of people from the States of Amazonas
(Northern Brazil), Maranhão and Ceará (Northeastern
Brazil).
During fifteen days of March (2007) women participat-
ing on the Juruti Project were offered systematic cervical
cancer screening (Pap smear test) combining conven-
tional cytology through Cytobrush Plus Cell Collector®(Coopersurgical, Trumbull, Connecticut, US) for optimal
collection of exfoliated cells and a commercialized version
of the line blot assay – Linear Array HPV Genotyping
Test® (Roche Molecular Systems, Alameda, CA) – when
they had their routine cervical smear performed in a
public hospital. The Juruti Project has been approved
by the Instituto Evandro Chagas, statement nº30/05,
CAAE 0013.0.072.000-06DC-2008-374. All women were
informed and gave their written consent to participate in
the study.
HPV cytological and molecular analysis
After samples collection cytobrush was immersed into
15 ml falcon tubes with 3ml of phosphate buffer saline
(PBS: 137 mM NaCl, 10 mM Phosphate buffer, 2,7 mM
KCl, pH 7.4) and kept at 4ºC according to the manufac-
turer’s instructions. At the HPV laboratory the falcon
tubes were submitted to manual agitation, followed by
cytobrush discard and centrifugation of the liquid per
fifteen minutes (1200 rpm). Supernatant was discarded
and cell pellet was resuspended in 3 mL of PBS solution.
The conventional cytology results were classified ac-
cording to the recommendations of Brazilian Ministry of
Health and Brazilian Society of Cytology which is based
on Bethesda’s definition [35] and were performed at Juruti
by the local routine professionals. Cervical specimen DNA
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HPV Genotyping Test® kit protocol (Roche Molecular
Systems, Alameda, CA), which can detect until thirty
seven distinct HPV types in a unique reaction, which
includes high and low risk and multiple infections. Only
the strips that had an internal positive control test (β-glo-
bin gene) were considered proper to genotyping analysis.
The PCR and sequencing of the HPV 16 E6 gene (nt
46-256) was performed as described by Chopjitt et al [5].
The amplification of E6 fragment was confirmed as
described beforey. The obtained nucleotide sequences of
the E6 region were edited and assembled using UGENE
software. Sequences were globally aligned and compared
with HPV variants sequences available at GenBank data-
base (GenBank accession number: K02718, NC_001526,
AF125673, AF536179, AF486310, AF472508, AF536180,
AF472509, AF486324, AF404705, AF534061, AF486299,
AF402678, AF486325) using MAFFT version 7 software.
Phylogenetic tree was constructed and edited using RaxML
version 7.0.4 (1.000 bootstraps) and Dendroscope version 3
software’s, respectively.
Statistical analysis
Data were analyzed with the software BioEstat 5.3 [36].
Fisher test was used to compare categorical variables
between two groups (HPV-infected and non-infected
women). Wilcoxon-Mann-Whitney test and G test were
used to verify a possible association between age and
HPV prevalence. After plotting HPV prevalence and
hrHPV prevalence among HPV-infected women, in each
age-group, a polynomial fit was assessed as the best
model for logistic regression.
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